Malignant Neoplasms
|
0.400 |
CausalMutation
|
group |
CGI |
|
|
|
Malignant Neoplasms
|
0.400 |
GenomicAlterations
|
group |
CGI |
|
|
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To investigate whether CDKN2B and CDKN2 are involved in esophageal tumorigenesis, we studied homozygous deletion, intragenic mutation, and messenger RNA (mRNA) expression of CDKN2 and CDKN2B in nine esophageal squamous cancer cell lines.
|
7547637 |
1995 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Molecular genetic studies have revealed that deletion of the p16 and p15 genes occurs frequently in cancer cell lines and in certain malignant neoplasms.
|
7563186 |
1995 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The tumor suppressor genes p16INK4A and p15INK4B map to the 9p21 chromosomal locus and are either homozygously deleted or mutated in a wide range of human cancer cell lines and tumors.
|
7632961 |
1995 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
PCR-single strand conformational polymorphism analysis of CDKN2 exons 2 and 3 and MTS2 exon 2 failed to demonstrate mutations in either CDKN2 or MTS2 in any of the T- or B-cell malignancies, with two possible exceptions.
|
7882348 |
1995 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
For example, the CDKI genes p16 and p15 are frequently deleted in various malignancies and are thought to contribute to cellular transformations.
|
8630967 |
1996 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The cell cycle regulators p16INK4 and p15INK4B have been mapped to the minimal region of overlap for chromosome 9p21 deletions, observed in a number of malignancies, suggesting that they could be tumor suppressor genes (TSGs).
|
8641406 |
1996 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Recently, two putative tumor suppressor gene(s) CDKN2 and MTS2, have been mapped to the 9p21 region, and have been shown to be deleted in a large number of hematopoietic and solid malignancies.
|
8689636 |
1996 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The p16 and p15 CDKI genes are very frequently altered in a variety of cancers including hematopoietic malignancies.
|
8946928 |
1996 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Structural genetic changes of tumor suppressor genes MTS-1/INK4A and MTS-2/INK4B were demonstrated in a variety of human cancers but not in thyroid cancer until now.
|
8957499 |
1996 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The results indicate that homozygous deletions of p16INK4 and/or p15INK4B genes may play a role in a subset of primary gynecologic malignancy.
|
9159345 |
1997 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
p18INK4C, a cyclin-dependent kinase inhibitor, is a homologue of p15INK4B and p16INK4A which are frequently altered in a variety of malignancies.
|
9401081 |
1997 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
The fact that the p16/INK4a and p15/INK4b genes are frequently inactivated in human malignancies and that p16/INK4a null mice spontaneously develop B-cell lymphomas prompted us to examine the status of both genes in Burkitt's Lymphoma (BL).
|
9473234 |
1998 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Messenger RNA (mRNA) analysis showed that CDKN2C is expressed in all hepatoblastoma samples studied, while both CDKN2A and CDKN2B genes are not transcribed in the cancer specimens as well as in the matched normal liver tissues.
|
9537438 |
1998 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Recently, p16 and p15 have been identified as commonly inactivated tumour suppressor genes in haematological malignancies.
|
9792305 |
1998 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In addition, a significant up-regulation of p15INK4B gene expression is observable during the development of the acute phase of malignancy.
|
9825572 |
1998 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Alterations of the INK4A and INK4B genes occur frequently in certain primary malignant neoplasms.
|
9890173 |
1999 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
On the other hand, hereditary mutations of TP57KIP2, P15INK4B, and P16INK4A, which affect the cell cycle similar to TP53, were observed in some types of cancer.
|
10484981 |
1999 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The reversibility of this epigenetic inactivation of the p16 and p15 genes in MM may also provide a broad clinical application in the development of new therapeutic interventions in this uniformly fatal form of cancer.
|
10492069 |
1999 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of the cyclin-dependent kinase inhibitor p15(INK4B) frequently is altered in myeloid malignancies.
|
10812241 |
2000 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cyclin-dependent kinase (CDK) inhibitors represented by the INK4 family (including p16(INK4a, CDKN2A), p15(INK4b, CDKN2B), p18(INK4c, CDKN2C), and p19(INK4d, CDKN2D)) are regulators of the cell cycle shown to be aberrant in many types of human cancer.
|
10918395 |
2000 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Alterations of p16 and p15 genes have been reported in cancer cell lines and in certain malignant neoplasm.
|
10958872 |
2000 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The genes encoding the cyclin-dependent kinase inhibitors p16INK4A and p15INK4B are potent TSGs, and correlations between their inactivation and disease progression have also been reported in various malignancies.
|
11243384 |
2001 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We have now analyzed a series of promoter hypermethylation changes in 12 genes (p16(INK4a), p15(INK4b), p14(ARF), p73, APC,(5) BRCA1, hMLH1, GSTP1, MGMT, CDH1, TIMP3, and DAPK), each rigorously characterized for association with abnormal gene silencing in cancer, in DNA from over 600 primary tumor samples representing 15 major tumor types.
|
11309270 |
2001 |